Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
7
SXTP Quote, Financials, Valuation and Earnings
Last price:
$2.91
Seasonality move
:
-46.57%
Day range:
$2.91 - $3.06
52-week range:
$1.36 - $17.68
Dividend yield:
0%
P/E ratio:
15.22x
P/S ratio:
1.48x
P/B ratio:
--
Volume:
14.3K
Avg. volume:
7M
1-year change:
-63.18%
Market cap:
$3.8M
Revenue:
$681.3K
EPS (TTM):
-$7.32
Analysts' Opinion
-
Consensus Rating60 Degrees Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.60, 60 Degrees Pharmaceuticals, Inc. has an estimated upside of 494.6% from its current price of $2.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.20 representing 100% downside risk from its current price of $2.96.
Fair Value
-
According to the consensus of 2 analysts, 60 Degrees Pharmaceuticals, Inc. has 494.6% upside to fair value with a price target of $17.60 per share.
SXTP vs. S&P 500
-
Over the past 5 trading days, 60 Degrees Pharmaceuticals, Inc. has underperformed the S&P 500 by -8.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
60 Degrees Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
60 Degrees Pharmaceuticals, Inc. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter 60 Degrees Pharmaceuticals, Inc. reported revenues of $528.6K.
Earnings Growth
-
60 Degrees Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter 60 Degrees Pharmaceuticals, Inc. reported earnings per share of -$0.66.
Enterprise value:
9.3M
EV / Invested capital:
--
Price / LTM sales:
1.48x
EV / EBIT:
27.43x
EV / Revenue:
6.89x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
21.64x
Gross Profit (TTM):
$575.1K
Return On Assets:
-132.46%
Net Income Margin (TTM):
-588.79%
Return On Equity:
-193.16%
Return On Invested Capital:
-186.16%
Operating Margin:
-439.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $529.3K | $451.8K | $1.4M | $148.1K | $528.6K | |
| Gross Profit | $108.7K | $38.9K | $575.1K | $36.4K | -$9.1K | |
| Operating Income | -$3.5M | -$9.5M | -$7.9M | -$2.1M | -$2.3M | |
| EBITDA | -$3.4M | -$9.5M | -$7.8M | -$2.1M | -$2.3M | |
| Diluted EPS | -$63.41 | -$82.40 | -$24.61 | -$0.93 | -$2.66 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $8.9M | $6.9M | $6.3M | |
| Total Assets | -- | -- | $9.2M | $7.4M | $6.7M | |
| Current Liabilities | -- | -- | $2.5M | $1.3M | $2.2M | |
| Total Liabilities | -- | -- | $2.6M | $1.5M | $2.3M | |
| Total Equity | -- | -- | $6.5M | $6M | $4.3M | |
| Total Debt | -- | -- | $161.4K | $156.7K | $153.8K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.5M | -$4.1M | -$6.8M | -$1.7M | -$2.1M | |
| Cash From Investing | -$108K | -$2M | $1.6M | -$1.7M | -$25.5K | |
| Cash From Financing | $6.4M | $7.1M | $6M | $5.2M | $4.3M | |
| Free Cash Flow | -$4.7M | -$4.3M | -$6.9M | -$1.7M | -$2.1M | |
SXTP
Sector
Market Cap
$3.8M
$25.8M
Price % of 52-Week High
16.74%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-275.12%
-1.64%
1-Year Price Total Return
-63.18%
-18.88%
Beta (5-Year)
--
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.08
200-day SMA
Sell
Level
$5.70
Bollinger Bands (100)
Sell
Level
2.76 - 5.42
Chaikin Money Flow
Sell
Level
-23.8K
20-day SMA
Sell
Level
$3.66
Relative Strength Index (RSI14)
Sell
Level
42.39
ADX Line
Sell
Level
33.42
Williams %R
Buy
Level
-91.1111
50-day SMA
Sell
Level
$3.18
MACD (12, 26)
Buy
Level
0.83
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-38.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.1156)
Sell
CA Score
(Annual)
Level (-5.9875)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (10.8579)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.
Stock Forecast FAQ
In the current month, SXTP has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SXTP average analyst price target in the past 3 months is $17.60.
-
Where Will 60 Degrees Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that 60 Degrees Pharmaceuticals, Inc. share price will rise to $17.60 per share over the next 12 months.
-
What Do Analysts Say About 60 Degrees Pharmaceuticals, Inc.?
Analysts are divided on their view about 60 Degrees Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 60 Degrees Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $11.20.
-
What Is 60 Degrees Pharmaceuticals, Inc.'s Price Target?
The price target for 60 Degrees Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $17.60 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SXTP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 60 Degrees Pharmaceuticals, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SXTP?
You can purchase shares of 60 Degrees Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 60 Degrees Pharmaceuticals, Inc. shares.
-
What Is The 60 Degrees Pharmaceuticals, Inc. Share Price Today?
60 Degrees Pharmaceuticals, Inc. was last trading at $2.91 per share. This represents the most recent stock quote for 60 Degrees Pharmaceuticals, Inc.. Yesterday, 60 Degrees Pharmaceuticals, Inc. closed at $2.96 per share.
-
How To Buy 60 Degrees Pharmaceuticals, Inc. Stock Online?
In order to purchase 60 Degrees Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SXTP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SXTP
Sector
P/E ratio
15.22x
23.44x
PEG ratio
0.00x
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
1.48x
1.56x
Growth Metrics
SXTP
Sector
Revenue growth
256.87%
3.27%
Earnings growth
28.52%
9.66%
Revenue (5-year growth)
--
6.43%
Earnings forecast
-$2.00
-$0.20
Profitability
SXTP
Sector
Profitability FY 2024
$296.6K
$2.3M
Return on invested capital
-186.16%
-33.49%
Return on assets
-132.46%
-29.74%
Return on equity
-193.16%
-39.33%
Earnings Date
Last Earnings Date
Aug
12
Next Earnings Date
Feb
27
Estimated Next Earnings Date
May
29
Balance Sheet
SXTP
Sector
Total cash
$4.1M
$24.2M
Short term investments
--
$23.8M
Total assets
$5.8M
$71.1M
Long term debt
$153.8K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 15.34% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.22% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.48% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
